250.24

1.70% -3.16

Axsome Therapeutics Inc (AXSM)

Overview News Price History Option Chain Financials Why AXSM Down? Discussions Forecast

Axsome Therapeutics Inc stock is traded at $250.24, with a volume of 51,661. It is down -1.70% in the last 24 hours and up +9.39% over the past month. Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Previous Close:

$253.40

Open:

$255.03

24h Volume:

51,661

Relative Volume:

0.07

Market Cap:

$12.85B

Revenue:

$708.24M

Net Income/Loss:

$-188.30M

P/E Ratio:

-66.92

EPS:

-3.7392

Net Cash Flow:

$-70.99M

1W Performance:

+1.41%

1M Performance:

+9.39%

6M Performance:

+69.61%

1Y Performance:

+144.96%

1-Day Range:

$248.08

$255.03

1-Week Range:

$245.11

$257.93

52-Week Range:

$96.09

$257.93

Axsome Therapeutics Inc Stock (AXSM) Company Profile

Name

Axsome Therapeutics Inc

Sector

Healthcare (1109)

Industry

Biotechnology (621)

Phone

(212) 332-3241

Address

ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK

Employee

925

Twitter

Next Earnings Date

2026-08-03

Latest SEC Filings

AXSM's Discussions on Twitter

Compare AXSM vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AXSM Axsome Therapeutics Inc	249.73	13.04B	708.24M	-188.30M	-70.99M	-3.7392
VRTX Vertex Pharmaceuticals Inc	448.25	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	611.06	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	873.33	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	279.31	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	157.49	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-24-26	Initiated	Wolfe Research	Outperform
Jan-08-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Oct-01-25	Initiated	B. Riley Securities	Buy
Sep-03-25	Resumed	Wells Fargo	Overweight
Jul-03-25	Resumed	Morgan Stanley	Overweight
Jun-03-25	Initiated	Oppenheimer	Outperform
Apr-07-25	Initiated	Jefferies	Buy
Feb-11-25	Initiated	Deutsche Bank	Buy
Dec-31-24	Reiterated	Mizuho	Outperform
Sep-03-24	Initiated	Wells Fargo	Overweight
Aug-06-24	Upgrade	BofA Securities	Neutral → Buy
Jul-22-24	Initiated	Needham	Buy
Apr-29-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Mar-19-24	Initiated	Robert W. Baird	Outperform
Feb-06-24	Initiated	UBS	Buy
Jan-25-24	Initiated	RBC Capital Mkts	Outperform
Dec-13-23	Initiated	Citigroup	Buy
Aug-08-23	Upgrade	BofA Securities	Underperform → Neutral
Jan-05-23	Initiated	Piper Sandler	Neutral
Nov-01-22	Initiated	Loop Capital	Buy
Sep-07-22	Resumed	Mizuho	Buy
Aug-10-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-10-21	Initiated	Berenberg	Buy
Jan-08-21	Initiated	Jefferies	Buy
Dec-16-20	Initiated	Mizuho	Buy
Sep-29-20	Initiated	BofA Securities	Underperform
Sep-10-20	Initiated	Morgan Stanley	Overweight
Apr-28-20	Reiterated	H.C. Wainwright	Buy
Apr-14-20	Initiated	Cowen	Outperform
Dec-30-19	Reiterated	H.C. Wainwright	Buy
Dec-17-19	Reiterated	H.C. Wainwright	Buy
Dec-16-19	Reiterated	Guggenheim	Buy
Oct-16-19	Initiated	Guggenheim	Buy
Sep-18-19	Initiated	William Blair	Outperform
May-28-19	Initiated	SunTrust	Buy
May-23-19	Reiterated	H.C. Wainwright	Buy
Apr-08-19	Initiated	SVB Leerink	Outperform
Mar-15-19	Reiterated	H.C. Wainwright	Buy
Oct-03-16	Resumed	Brean Capital	Buy
Dec-15-15	Initiated	Cantor Fitzgerald	Buy
Dec-14-15	Initiated	Ladenburg Thalmann	Buy

View All

Axsome Therapeutics Inc Stock (AXSM) Latest News

03:30 AM

3 Under-the-Radar Stocks to Buy and Hold for a Decade - The Motley Fool

03:30 AM

Jun 15, 2026

Axsome presents data on narcolepsy treatments at sleep conference By Investing.com - Investing.com South Africa

Jun 15, 2026

Axsome presents data on narcolepsy treatments at sleep conference - Investing.com

Jun 15, 2026

Axsome Therapeutics Presents New Data on AXS-12 and Solriamfetol at SLEEP 2026 Conference - Quiver Quantitative

Jun 15, 2026

Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026 - GlobeNewswire

Jun 15, 2026

Axsome Therapeutics (AXSM) Stock Analysis: 57% Revenue Growth Propels Exciting Prospects - DirectorsTalk Interviews

Jun 15, 2026

Landscape Capital Management L.L.C. Sells 3,983 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat

Jun 15, 2026

Jun 14, 2026

First Turn Management LLC Has $37.79 Million Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat

Jun 14, 2026

Nicholas Investment Partners LP Purchases 42,907 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat

Jun 14, 2026

Eventide Asset Management LLC Sells 175,172 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat

Jun 14, 2026

Jun 13, 2026

The Technical Signals Behind (AXSM) That Institutions Follow - Stock Traders Daily

Jun 13, 2026

Rhenman & Partners Asset Management AB Reduces Stake in Axsome Therapeutics, Inc. $AXSM - MarketBeat

Jun 13, 2026

Jun 12, 2026

Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock - Stocktwits

Jun 12, 2026

Jun 11, 2026

Axsome therapeutics director Roger Jeffs sells $141,655 in shares By Investing.com - Investing.com India

Jun 11, 2026

Axsome therapeutics director Roger Jeffs sells $141,655 in shares - Investing.com UK

Jun 11, 2026